Cefuroxime Dosing for Acute Bacterial Tonsillitis
For acute bacterial tonsillitis (Group A Streptococcal pharyngitis), cefuroxime axetil 500 mg twice daily for 10 days is the recommended dose in adults, and 30 mg/kg/day divided into two doses (maximum 500 mg per dose) for 10 days in children.
Rationale and Evidence Base
The 2012 IDSA guideline for Group A Streptococcal pharyngitis establishes cefuroxime axetil as a first-line alternative to penicillin for patients with penicillin allergy (non-Type I hypersensitivity) 1. The guideline specifically recommends cefuroxime axetil 500 mg twice daily for adults and 30 mg/kg/day in two divided doses (maximum 500 mg per dose) for children, administered for 10 days 1.
The FDA drug label confirms these dosing parameters, noting that a minimum of 10 days of treatment is recommended for infections caused by Streptococcus pyogenes to guard against the risk of rheumatic fever or glomerulonephritis 2.
Clinical Efficacy Data
Multiple randomized controlled trials demonstrate cefuroxime axetil's effectiveness:
- Bacteriological eradication rates: Studies show 90-94% eradication rates with cefuroxime axetil versus 67-84% with penicillin V 3, 4, 5
- Clinical success: 97-98% clinical success rates have been documented 3
- Prevention of sequelae: A large German study with 1-year follow-up found no post-streptococcal sequelae in cefuroxime-treated patients, with only one case of glomerulonephritis occurring in the penicillin V group 4
Recent network meta-analysis data (2026) confirms cefuroxime axetil demonstrates significantly superior early clinical response compared to penicillin V (OR: 2.14; 95% CI: 1.19-3.60) 6.
Dosing Specifics by Age
Adults and adolescents ≥13 years:
- 500 mg twice daily for 10 days 1
Children:
- 30 mg/kg/day divided into 2 doses (maximum 500 mg per dose) for 10 days 1
- Alternative pediatric dosing from FDA label: 20 mg/kg twice daily (maximum 500 mg/dose) 2
Important Clinical Considerations
Duration is critical: The 10-day course must be completed to prevent rheumatic fever and glomerulonephritis, even if symptoms resolve earlier 2. This is explicitly stated in FDA labeling and supported by guideline recommendations.
Penicillin allergy context: Cefuroxime should be avoided in patients with immediate Type I hypersensitivity reactions to penicillin 1. For non-immediate reactions (e.g., rash), cephalosporins like cefuroxime are appropriate alternatives.
Comparative advantage: Cefuroxime axetil offers twice-daily dosing versus three-times-daily penicillin V, potentially improving adherence 3, 4. Studies demonstrate this convenience does not compromise efficacy and may actually improve bacteriological outcomes.
Antimicrobial stewardship note: While cefuroxime is effective, penicillin V remains the preferred first-line agent when appropriate to preserve narrow-spectrum antibiotic use 1, 6. Cefuroxime should be reserved for penicillin-allergic patients or treatment failures.
Formulation Considerations
Pharmacokinetic analysis shows the oral suspension formulation achieves higher drug exposure than tablets, covering MICs up to 1.0 mg/L versus 0.5 mg/L for tablets 7. This may be relevant for pediatric dosing or resistant organisms, though standard dosing remains appropriate for typical GAS pharyngitis.